Enliven Therapeutics, Inc. (ELVN)
36.98
+0.87
(+2.41%)
USD |
NASDAQ |
Jun 10, 16:00
38.29
+1.31
(+3.54%)
After-Hours: 20:00
Enliven Therapeutics 1 Year Total Returns (Daily) : 77.53% for June 9, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| June 09, 2026 | 77.53% |
| June 08, 2026 | 62.15% |
| June 05, 2026 | 62.42% |
| June 04, 2026 | 59.22% |
| June 03, 2026 | 64.82% |
| June 02, 2026 | 85.58% |
| June 01, 2026 | 111.1% |
| May 29, 2026 | 123.1% |
| May 28, 2026 | 153.0% |
| May 27, 2026 | 159.0% |
| May 26, 2026 | 159.3% |
| May 22, 2026 | 147.7% |
| May 21, 2026 | 149.6% |
| May 20, 2026 | 140.9% |
| May 19, 2026 | 138.4% |
| May 18, 2026 | 135.1% |
| May 15, 2026 | 132.0% |
| May 14, 2026 | 116.6% |
| May 13, 2026 | 117.5% |
| May 12, 2026 | 122.5% |
| May 11, 2026 | 114.9% |
| May 08, 2026 | 118.7% |
| May 07, 2026 | 120.5% |
| May 06, 2026 | 109.2% |
| May 05, 2026 | 103.9% |
| Date | Value |
|---|---|
| May 04, 2026 | 102.9% |
| May 01, 2026 | 110.1% |
| April 30, 2026 | 117.7% |
| April 29, 2026 | 127.3% |
| April 28, 2026 | 127.3% |
| April 27, 2026 | 146.6% |
| April 24, 2026 | 141.8% |
| April 23, 2026 | 147.0% |
| April 22, 2026 | 147.3% |
| April 21, 2026 | 182.9% |
| April 20, 2026 | 180.8% |
| April 17, 2026 | 191.0% |
| April 16, 2026 | 182.1% |
| April 15, 2026 | 157.8% |
| April 14, 2026 | 160.9% |
| April 13, 2026 | 165.5% |
| April 10, 2026 | 204.0% |
| April 09, 2026 | 176.0% |
| April 08, 2026 | 171.4% |
| April 07, 2026 | 141.5% |
| April 06, 2026 | 108.3% |
| April 02, 2026 | 95.52% |
| April 01, 2026 | 100.2% |
| March 31, 2026 | 99.19% |
| March 30, 2026 | 73.66% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Cocrystal Pharma, Inc. | -38.18% |
| CNBX Pharmaceuticals, Inc. | -85.83% |
| GB Sciences, Inc. | -25.00% |
| Arvinas, Inc. | -7.92% |
| Fulcrum Therapeutics, Inc. | -50.56% |